Sep 30, 2026 07:00AM
Sep 30, 2026 07:00AM
Jun 11, 2026 07:30AM
Jun 10, 2026 07:30AM
Jun 10, 2026 07:30AM
Jun 18, 2025 07:00AM
Jun 18, 2025 07:00AM Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Wee
Dec 11, 2024 07:00AM
Nov 6, 2024 07:14PM
May 30, 2024 09:00AM
Sep 28, 2022 07:00AM
Aug 3, 2022 08:00AM
Jul 6, 2022 08:00AM
Jun 27, 2022 08:00AM Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastroint
Jun 16, 2022 02:14PM
Jun 16, 2022 08:00AM
Jun 1, 2022 08:00AM
May 24, 2022 11:06AM
May 24, 2022 11:04AM
May 19, 2022 09:00AM
Jan 18, 2022 08:30AM Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Pat
Jan 18, 2022 08:30AM
Jan 6, 2022 08:30AM
Jan 6, 2022 08:30AM
Dec 13, 2021 08:00AM
Dec 13, 2021 08:00AM
Nov 11, 2021 09:00AM
Nov 11, 2021 09:00AM Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma
Nov 3, 2021 09:03AM
Nov 3, 2021 09:00AM
Nov 3, 2021 09:00AM
Oct 28, 2021 08:02AM
Oct 28, 2021 08:00AM
Oct 28, 2021 08:00AM
Oct 28, 2021 07:02AM Rafael Holdings (RFL) Announces CPI-613 Did Not Meet Primary Endpoints in Phase 3 Trial
Oct 28, 2021 07:00AM
Oct 28, 2021 07:00AM
Oct 18, 2021 04:30PM
Sep 27, 2021 08:00AM
Sep 27, 2021 08:00AM
Aug 26, 2021 08:00AM
Aug 26, 2021 08:00AM President and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021
Aug 25, 2021 10:02AM
Aug 25, 2021 10:00AM
Aug 25, 2021 10:00AM
Aug 17, 2021 10:11AM
Jul 1, 2021 08:01AM
Jul 1, 2021 08:00AM
Jul 1, 2021 08:00AM Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Jun 30, 2021 08:00AM

333,569 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All